Latest Oncolytic virus Stories
CALGARY, June 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted its 35th U.S.
The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma.
SAN FRANCISCO and WASHINGTON, May 20 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today reported positive results from its Phase 1 dose escalation study evaluating the intravenous (IV) administration of JX-594 to patients with metastatic cancer.
The researchers of the University of Helsinki, and Oncos Therapeutics, the biotech company developing new cancer therapeutics based on the next generation oncolytic viruses, published initial results from their Advanced Therapy Access Program in Cancer Research.
SAN FRANCISCO, May 13 /PRNewswire/ -- Jennerex, Inc., a clinical-stage cancer biotherapeutics company, today announced that key data from its JX-594 intravenous administration Phase 1 dose escalation clinical study will be presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place May 19-22, 2010, in Washington DC. The presentation details are as follows: Abstract #33: "Demonstration of Delivery and Antitumoral Activity of JX-594, a Targeted...
Complete regression of malignant brain tumors after treatment with parvoviruses.
SAN FRANCISCO, April 28 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today expanded its board of directors with the appointment of Paul B.
BATON ROUGE, La., April 20 /PRNewswire/ -- Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies.
SAN FRANCISCO and VIENNA, April 19 /PRNewswire/ -- Jennerex, Inc.
CALGARY, April 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.
- To give a box on the ear to.